In this multicenter phase 1 trial, patients with advanced gastric and gastroesophageal junction cancer were safely treated with the CLDN18.2-targeting antibody–drug conjugate SHR-A1904, leading to encouraging objective response rates.
- Dan-Yun Ruan
- Hao-Xiang Wu
- Rui-Hua Xu